Assessment of Potential Sources of Variability on the Analytical Performance of a Circulating Tumor DNA Minimal Residual Disease Test for B‐Cell Lymphomas
Journal of Clinical Laboratory Analysis · 2026-06 · 40 (11)
DOI: 10.1002/jcla.70258 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Laboratory Analysis, online erschienen am 06.05.2026. Verfasst von Nina Klimova und 7 weiteren Autor:innen. Beteiligte Einrichtung: Foresight Diagnostics, Inc., Boulder, Colorado, USA. Hauptthemen laut MEDLINE: Circulating Tumor DNA, Neoplasm, Residual, Lymphoma, B-Cell. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Aims
To evaluate the robustness of circulating tumor DNA minimal residual disease (ctDNA‐MRD) test results to common factors that could impact performance.
Methods
DNA from three sample types is required: somatic, germline, and MRD monitoring. Different sample sources were evaluated for germline [whole blood, peripheral blood mononuclear cells (PBMCs)] and somatic (pre‐treatment plasma, tumor) samples. Extraction methods, common interfering substances, and DNA input mass were evaluated for impact on MRD determination. Each comparison was performed in isolation. Overall test variability was also evaluated.
Results
Whole blood and PBMCs were acceptable germline sample types, with minimal differences in identification of somatic variants. Both pre‐treatment plasma and tumor were acceptable somatic sample types, achieving the same 95% hit rate of three mutant molecules. Agreement between results from different extraction methods and in the presence of interfering substances was 100%. Positive percent agreement (PPA) between results from DNA input masses above and below the test upper and lower limits decreased, though PPA was 100% between 4 ng and the lower limit (5 ng). Variance in test performance fell within acceptable ranges (coefficient of variation 4.95%–10.33%).
Conclusions
Major potential sources of variation and interference did not significantly impact ctDNA‐MRD test performance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Foresight Diagnostics, Inc., Boulder, Colorado, USA.
Zitieren
APA
Klimova, N., Roff, A., McCutcheon, J., Aheimer, A., Close, S. L., Hockett, R. D., Meek, S., & Hyland, L. (2026). Assessment of Potential Sources of Variability on the Analytical Performance of a Circulating Tumor DNA Minimal Residual Disease Test for B‐Cell Lymphomas. Journal of Clinical Laboratory Analysis, 40(11). https://doi.org/10.1002/jcla.70258
Vancouver
Klimova N, Roff A, McCutcheon J, Aheimer A, Close SL, Hockett RD, et al. Assessment of Potential Sources of Variability on the Analytical Performance of a Circulating Tumor DNA Minimal Residual Disease Test for B‐Cell Lymphomas. Journal of Clinical Laboratory Analysis. 2026;40(11). doi:10.1002/jcla.70258
BibTeX
@article{Klimova2026,
author = {Klimova, Nina and Roff, Alanna and McCutcheon, Justine and Aheimer, Alex and Close, Sandra L and Hockett, Richard D and Meek, Stephanie and Hyland, Laura},
title = {Assessment of Potential Sources of Variability on the Analytical Performance of a Circulating Tumor DNA Minimal Residual Disease Test for B‐Cell Lymphomas},
journal = {Journal of Clinical Laboratory Analysis},
year = {2026},
volume = {40},
number = {11},
doi = {10.1002/jcla.70258}
}
EUVIMED